Artemis Medicare Services Limited has informed the Exchange regarding Outcome of Board Meeting held on May 12, 2025.
ARTEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 3.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. FY25 revenue from operations rose to Rs. 91,326 lakhs from Rs. 84,523 lakhs in FY24 (~8% growth). Net profit after tax jumped to Rs. 8,346 lakhs from Rs. 4,915 lakhs (~70% YoY growth), with EPS rising to Rs. 5.42 from Rs. 3.62. The board recommended a final dividend of Rs. 0.45 per share (45%) subject to shareholder approval. The company also issued Compulsorily Convertible Debentures of Rs. 33,000 lakhs to IFC earlier in the year, boosting cash reserves significantly. Mr. Sunam Sarkar was appointed as an Additional Director, while Dr. Nirmal Kumar Ganguly resigned citing personal reasons. DMK Associates was appointed as Secretarial Auditor for five years.
Strong profit growth driven by both revenue expansion and margin improvement (EBITDA margin expanded notably from ~16% to ~20%). The healthy 45% dividend signals confidence in cash flows, though the Rs. 33,000 lakh CCD issuance will lead to equity dilution upon conversion. Overall a positive earnings outcome for shareholders.